FCMI
BLUE

Foresite Capital Management IV’s bluebird bio BLUE Stock Holding History

Foresite Capital Management IV’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-3,860
Closed -$2.3M – 13
2020
Q1 		$2.3M Buy
+3,860
New +$3.76M 2.83% 8

Other funds holding BLUE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Foresite Capital Management IV's BLUE Position: Q2 2020 in Review

Foresite Capital Management IV sold out of bluebird bio (BLUE) in Q2 2020, closing a stake of 3,860 shares — an estimated $2.3M sold.

Foresite Capital Management IV first reported a position in BLUE in Q1 2020 and held it in 1 quarter. The position peaked at $2.3M in Q1 2020. 278 funds tracked by Wall St. Rank hold BLUE as of Q2 2020.

  • Foresite Capital Management IV reported no remaining bluebird bio position as of Q2 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 3,860 bluebird bio shares in Q2 2020, an estimated $2.3M.
  • Foresite Capital Management IV first reported a position in bluebird bio in Q1 2020 and held it in 1 quarter.
  • Foresite Capital Management IV's bluebird bio position peaked at $2.3M in Q1 2020.
  • 278 funds tracked by Wall St. Rank held bluebird bio as of Q2 2020.

Based on Foresite Capital Management IV's 13F filing for Q2 2020, filed 13 Aug 2020.